GlassScriptPhysician profile
Nikhil Balakrishnan
NPI 1396993184
$3,290.25
in general payments reported to CMS, 2019-2025
32 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $203 · 2021: $451 · 2022: $456 · 2023: $722 · 2024: $712 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $492.27 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $442.10 | 2020-2025 | Xcopri |
| Abbvie INC. | $362.94 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $326.55 | 2019-2022 | |
| Lilly USA, LLC | $221.48 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $183.01 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $160.85 | 2021-2024 | Qelbree |
| Pfizer INC. | $117.14 | 2023-2025 | |
| Eisai INC. | $112.68 | 2024-2025 | |
| Mdd US Operations, LLC | $110.25 | 2024-2025 | Gocovri, Xadago, Apokyn |
| Biogen, INC. | $97.00 | 2023-2025 | Vumerity |
| E.R. Squibb & Sons, L.L.C. | $88.49 | 2022 | |
| Lundbeck LLC | $77.89 | 2022-2023 | Rexulti, Vyepti |
| Aucta Pharmaceuticals, INC. | $60.35 | 2024-2025 | Motpoly Xr |
| Ucb, INC. | $59.33 | 2023-2025 | Rystiggo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $37.38 | 2023-2024 | Valtoco |
| Csl Behring | $36.36 | 2024 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $35.96 | 2024-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $25.88 | 2022 | |
| Avion Pharmaceuticals | $21.23 | 2023 | Dhivy |
| Biohaven Pharmaceutical Holding Company LTD. | $21.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.96 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.95 | 2022 | |
| Amneal Pharmaceuticals LLC | $20.11 | 2025 | Crexont |
| Scilex Pharmaceuticals INC. | $19.82 | 2024 | |
| Merz Pharmaceuticals, LLC | $19.66 | 2025 | Xeomin |
| Abbott Laboratories | $19.09 | 2023 | Infinity |
| Collegium Pharmaceutical, INC. | $18.00 | 2022 | |
| Janssen Biotech, INC. | $16.59 | 2025 | |
| Novo Nordisk INC | $16.17 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.08 | 2023 | Quviviq |
| Amgen INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Balakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.